News + Font Resize -

Colorcon completes expansion of its Goa facility with an investment of Rs.70 crore
Our Bureau, Mumbai | Wednesday, April 30, 2014, 15:30 Hrs  [IST]

With an investment of Rs.70 crore, Colorcon, one of the leading global excipient companies, completed the final phase of the capacity building initiative of its South Asia production facility in Verna, Goa, India. The company informed that the incremental manufacturing capacity is evidence of Colorcon’s ongoing commitment to the Indian pharma and nutraceutical industries.

The Goa plant is one of six Colorcon manufacturing plants dedicated to film coatings.  These plants are strategically located close to key customer centers in India, China, Europe, North America and Japan. The Goa site operates under Schedule M of the Indian FDA and IPEC guidelines, with Colorcon accredited to the latest ISO 9001 standard.

Subodh Priolkar, regional managing director for South Asia said the investment would enable Colorcon to continue in meeting the needs of its customers through security of supply and short lead times.

“Having established in the region for over 30 years, Colorcon is proud to be the supplier of choice for film coatings and excipients to the pharma industry in India and South Asia. We are excited about the plant expansion and are well positioned to continue supporting the growth of our customers in the region. Our customers value our commitment to the region and our ability to support them throughout the entire product lifecycle, from the product design stage to production with services like tablet design, technical and regulatory support,” Priolkar informed.

Colorcon provides industry leading film coatings, modified release technologies, functional excipients and tablet design services to the pharma industry. Its products meet the highest standards for quality, efficiency and safety.

Martti Hedman, CEO of Colorcon, said “India is one of the fastest growing pharma markets due to improving standard of living, easier access to western medicine and increase of lifestyle diseases. India is also the most important production cluster of generic medicines for global markets. Colorcon is investing heavily in India to support its customers during both development and manufacture. Speed to market, cost to produce and consistently high product quality are our customers’ strategic objectives. Colorcon continues to work relentlessly to help our customers to meet these objectives better than any other supplier.”

Post Your Comment

 

Enquiry Form